|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
4.780 +0.100 (+2.137%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 6,542,690 | -2.914% | 6,739,100 | 5,712,259 | 5,007,536 | 4,024,155 |
| Cost of Sales | (4,278,866) | -4.193% | (4,466,133) | (3,331,598) | (2,643,912) | (2,310,364) |
| Gross Profit | 2,263,824 | -0.402% | 2,272,967 | 2,380,661 | 2,363,624 | 1,713,791 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (109,083) | 14.904% | (94,934) | (137,588) | (171,730) | (118,925) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (613) | 559.140% | (93) | (17) | -- | -- | |
| Share of Results of Asso. & JCEs | 13,636 | 161.527% | 5,214 | 5,840 | 7,134 | 4,667 | |
| Profit / (Loss) before Taxation | 1,618,674 | 3.464% | 1,564,475 | 1,504,802 | 1,475,514 | 1,128,193 | |
| Taxation | (366,501) | -0.871% | (369,721) | (328,442) | (349,991) | (267,215) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (79,209) | 44.276% | (54,901) | (51,167) | (39,967) | (17,776) | |
| Others | (35,729) | -16.507% | (42,793) | (35,828) | (35,600) | (49,800) | |
| Profit / (Loss) Attributable to Shareholders | 1,137,235 | 3.662% | 1,097,060 | 1,089,365 | 1,049,956 | 793,402 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (6,014) | -82.460% | (34,288) | (23,108) | (7,917) | (7,926) |
| Depreciation & Amortisation | 262,063 | 7.041% | 244,826 | 196,609 | 155,988 | 133,937 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 60.000 | 3.448% | 58.000 | 58.000 | 57.000 | 46.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 8.940 | -- | 7.738 | 6.987 | 6.496 | 5.740 |
| Remarks: | Real time quote last updated: 02/12/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,137,235 |
| %Change | 3.662% |
| EPS / (LPS) | RMB 0.600 |
| NBV Per Share (¥) | RMB 8.940 |